Join us in celebrating the up-and-coming leaders who are vital to the future of the pharmaceutical and biotech industry.
In order to nominate yourself or someone you think is an emerging pharma leader, first consider the qualities, knowledge, skills, and activities of the nominee. Are they headed for the c-suite? Do they have what it takes to make the tough decisions that will continue to face manufacturers in the coming years? Can they navigate the commercial, financial, scientific, R&D, marketing, sales, and/or market access with leadership and inspiration? Do they have what it takes to get to the next level?
To review the accomplishments of 2022 winners, read here.
Entries are judged solely on responses. Please be as complete and descriptive as possible.
The deadline for entries is February 26, 2023 at 11:59 pm EST.
If you have any questions on the entry process, please contact the organizers by email here.
To sign up and submit a nomination, click here.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.